Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

78

Enrollment

OTHER

Sponsor class

Stopped insufficient enrollment and retention

Conditions

Oxidative Stress
Endothelial Dysfunction

Interventions

DRUG: valsartan (ARB)
DRUG: ramipril (ACE inhibitor)
DRUG: Placebo

Sponsor

Vanderbilt University

Collaborators

[object Object]
[object Object]